Clinical Collaboration Agreement Between Teva And Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Rescue Inhaler Respiratory Program

Teva Pharmaceutical Industries Ltd TEVA:

• CLINICAL COLLABORATION AGREEMENT BETWEEN TEVA AND LAUNCH THERAPEUTICS TO ACCELERATE DEVELOPMENT OF DUAL-ACTION ASTHMA RESCUE INHALER (ICS-SABA/TEV-’248) RESPIRATORY PROGRAM; TEVA AND ABINGWORTH ENTER STRATEGIC DEVELOPMENT FUNDING AGREEMENT

• TEVA: STRATEGIC DEVELOPMENT FUNDING AGREEMENT IN WHICH ABINGWORTH PROVIDES TEVA UP TO $150 MILLION TO OFFSET TEVA'S ICS/SABA (TEV-'248) PROGRAM COSTS

• TEVA: IF TEV-'248 GETS U.S. FDA APPROVAL, ABINGWORTH WILL BE ELIGIBLE TO RECEIVE FIXED PAYMENTS AS WELL AS SUCCESS PAYMENTS BASED ON ICS/SABA SALES